Osteoporosis New drugs Review
14.9K views | +1 today
Follow
 
Scooped by Krishan Maggon
onto Osteoporosis New drugs Review
Scoop.it!

Denosumab for Prevention of Osteoporosis in Renal Transplant Recipients

Denosumab for Prevention of Osteoporosis in Renal Transplant Recipients | Osteoporosis New drugs Review | Scoop.it
Conditions:   Osteoporosis;   Chronic Kidney DiseaseIntervention:   Drug: Denosumab (Prolia)Sponsor:   University of ZurichRecruiting - verified June 2011...
more...
No comment yet.
Osteoporosis New drugs Review
Denosumab is a breakthrough fully human monoclonal antibody approved by both the FDA and EMA in 2010. It had been fast tracked by FDA for treatment and prevention of postmenopausal osteoporosis, treatment and prevention of bone loss in hormone treated prostate and breast cancer patients. The FDA advisory committee (August 13, 2009) to review the safety and efficacy had recommend approval for treatment of high risk bone loss postmenopausal osteoporosis in women and hormone ablation treated men with prostate cancer, with black box warnings for serious side effects and under REMS program. Denosumab may have peak sales in the range of $5 billion within 5 years after approval in US, Europe, Japan and other major markets. New additional indications may follow and it may cross sales of $1 billion in 2012 due to unmet medical need from patients and healthcare providers. Clinical data published and in public domain indicates a superior safety and efficacy profile. FDA has asked for modifications and details of the REMS for treatment of osteoporosis. Denosumab (Prolia, Amgen) after FDA Review was approved under REMS on 1 June 2010. For prevention of osteoporosis and cancer indications, FDA has asked for new studies to show that there was no incidence of increased cancer. Amgen has submitted the BLA for prevention of bone loss in cancer patients on 14 June 2010. FDA had granted it the priority review status and approved the use for reducing fractures and other bone problems in cancer patients on 18 November, 2010. The European Committee for Human Medicinal Products CHMP recommended its approval in December 2009. It was approved by the EMA on 28 may 2010 and was launched there in the 3Q2010. Data presented at the ASCO and ESMO 2010 meetings has been added. The UK cost control agency NICE has recommended the clinical use of Prolia in osteoporosis. Data presented at EULAR showed increased bone density in women taking denosumab for 6 years and significantly reduced risk of fractures in elderly patients. The drug is approved in Switzerland for the prevention of bone loss in breast and prostate cancer patients undergoing hormone therapy besides osteoporosis. Sales of the drug were $33 million in 2010 and peak potential sales of over $ 5 billion per year.
Curated by Krishan Maggon
Your new post is loading...
Your new post is loading...
Scooped by Krishan Maggon
Scoop.it!

Denosumab (Prolia, Amgen) FDA Review & Approval - Krishan Maggon

Denosumab (Prolia, Amgen) FDA Review & Approval - Krishan Maggon | Osteoporosis New drugs Review | Scoop.it
Denosumab is a breakthrough fully human monoclonal antibody approved by both the FDA and EMA in 2010. It had been fast...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Stem Cell Therapy for Spinal Cord Injuries, Spinal Cord Injury Treatment

Stem Cell Therapy for Spinal Cord Injuries, Spinal Cord Injury Treatment | Osteoporosis New drugs Review | Scoop.it
Stem Cell Therapy helps to treat the Spinal cord injuries. Stem cell therapy repairs the damage tissues and cells of Spinal Cord. Call us today at +91-9654321400.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

The RANK/RANKL/OPG System in Tumorigenesis and Metastasis of Cancer Stem Cell: Potential Therapeutic Targets for Anticancer Therapy

The RANK/RANKL/OPG System in Tumorigenesis and Metastasis of Cancer Stem Cell: Potential Therapeutic Targets for Anticancer Therapy | Osteoporosis New drugs Review | Scoop.it
Even though the role of molecular triad involving receptor activator of nuclear factor kß (RANK)/RANK Ligand/ Osteoprotegrin (RANK/RANKL/OPG) cytokine system has be..
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

EMA/CHMP recommends Spherox (CO.DON AG.) new advanced therapy to repair cartilage defects in the knee

EMA/CHMP recommends Spherox (CO.DON AG.) new advanced therapy to repair cartilage defects in the knee | Osteoporosis New drugs Review | Scoop.it
New advanced therapy to repair cartilage defects in the knee Spherox recommended for marketing authorisation 

 The European Medicines Agency (EMA) has recommended granting a marketing authorisation in the European Union (EU) for a new advanced therapy medicinal product (ATMP) to treat adult patients who have symptomatic articular cartilage defects in the femoral condyle (the ball-shaped end of the thigh bone in the knee) and the patella (knee cap), where the size of the affected area is no larger than 10 cm².

The effects of Spherox were studied in two clinical trials, with patients between 18 and 50 years of age. The first study, a phase II trial, included 75 patients with cartilage defect sizes from 4 to 10 cm² and, the second, a phase III trial, involved 102 patients with defect sizes from 1 to 4 cm². The effect of the treatment was assessed using the Knee injury and Osteoarthritis Outcome Score (KOOS) questionnaire which evaluates patients’ views on their knee-associated problems, such as pain, impact on daily living, sport and recreational activities, and quality of life. Statistically significant improvement of the score was seen in both studies. 

 The most important adverse events reported in the studies were side effects that are often seen after surgery of the knee such as delayed wound healing, joint lock, joint effusion, and joint swelling, as well as very limited or single cases of venous thrombosis and pulmonary embolism.
Krishan Maggon 's insight:
Spherox is an ATMP composed of spheroids, i.e. spherical aggregates of chondrocytes (cells that are found in healthy cartilage). In this therapy, a small piece of cartilage is excised from the healthy cartilage and chrondrocyte spheroids are produced in a laboratory. These spheroids are then inserted arthroscopically in the patient knee where they form new tissue to heal the defect.

Spherox was assessed by the Committee for Advanced Therapies (CAT), EMA’s specialised scientific committee for ATMPs, such as gene or cell therapies. At its May 2017 meeting, the CAT recommended a positive opinion for Spherox to the Committee for Medicinal Products for Human Use (CHMP). The CHMP agreed with the CAT’s recommendation and adopted a positive opinion for the authorisation of Spherox across the EU at its 15-18 May 2017 meeting. The applicant received scientific advice from the Agency during the development of Spherox.

more...
Krishan Maggon 's curator insight, May 22, 3:46 AM
Spherox is an ATMP composed of spheroids, i.e. spherical aggregates of chondrocytes (cells that are found in healthy cartilage). In this therapy, a small piece of cartilage is excised from the healthy cartilage and chrondrocyte spheroids are produced in a laboratory. These spheroids are then inserted arthroscopically in the patient knee where they form new tissue to heal the defect. 

 Spherox was assessed by the Committee for Advanced Therapies (CAT), EMA’s specialised scientific committee for ATMPs, such as gene or cell therapies. At its May 2017 meeting, the CAT recommended a positive opinion for Spherox to the Committee for Medicinal Products for Human Use (CHMP). The CHMP agreed with the CAT’s recommendation and adopted a positive opinion for the authorisation of Spherox across the EU at its 15-18 May 2017 meeting. The applicant received scientific advice from the Agency during the development of Spherox. 

Scooped by Krishan Maggon
Scoop.it!

Juvenile Stem Cells Better at Bone Regeneration | Orthopedics This Week

Juvenile Stem Cells Better at Bone Regeneration | Orthopedics This Week | Osteoporosis New drugs Review | Scoop.it
Juvenile Stem Cells Better at Bone Regeneration
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Key stem cells for repairing knee joints identified

Key stem cells for repairing knee joints identified | Osteoporosis New drugs Review | Scoop.it
Stem cells that seem key for maintaining and repairing the body's knee joints have been identified by scientists.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Dual Therapeutic Action of a Neutralizing Anti-FGF2 Aptamer in Bone Disease and Bone Cancer Pain

Dual Therapeutic Action of a Neutralizing Anti-FGF2 Aptamer in Bone Disease and Bone Cancer Pain | Osteoporosis New drugs Review | Scoop.it
Fibroblast growth factor 2 (FGF2) plays a crucial role in bone remodeling and disease
progression. However, the potential of FGF2 antagonists for treatment of patients
with bone diseases has not yet been explored. Therefore, we generated a novel RNA
aptamer, APT-F2, specific for human FGF2 and characterized its properties in vitro
and in vivo. APT-F2 blocked binding of FGF2 to each of its four cellular receptors,
inhibited FGF2-induced downstream signaling and cells proliferation, and restored
osteoblast differentiation blocked by FGF2.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

A Magnetically Actuated Microscaffold Containing Mesenchymal Stem Cells for Articular Cartilage Repair

A Magnetically Actuated Microscaffold Containing Mesenchymal Stem Cells for Articular Cartilage Repair | Osteoporosis New drugs Review | Scoop.it
This study proposes a magnetically actuated microscaffold with the capability of targeted mesenchymal stem cell (MSC) delivery for articular cartilage regeneration. The microscaffold, as a 3D porou
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

MiR-19a regulates the cell growth and apoptosis of osteosarcoma stem cells by targeting PTEN. - PubMed - NCBI

MiR-19a regulates the cell growth and apoptosis of osteosarcoma stem cells by targeting PTEN. - PubMed - NCBI | Osteoporosis New drugs Review | Scoop.it
Tumour Biol. 2017 May;39(5):1010428317705341. doi: 10.1177/1010428317705341.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

The effect of equiaxial stretching on the osteogenic differentiation and mechanical properties of human adipose stem cells

The effect of equiaxial stretching on the osteogenic differentiation and mechanical properties of human adipose stem cells | Osteoporosis New drugs Review | Scoop.it
Publication date: August 2017
Source:Journal of the Mechanical Behavior of Biomedical Materials, Volume 72
Author(s): Sanni Virjula, Feihu Zhao, Joni Leivo, Sari Vanhatupa, Joose Kreutzer, Ted J. Vaughan, Anna-Maija Honkala, Marlitt Viehrig, Conleth A. Mullen, Pasi Kallio, Laoise M. McNamara, Susanna Miettinen
Although mechanical cues are known to affect stem cell fate and mechanobiology, the significance of such stimuli on the osteogenic differentiation of human adipose stem cells (hASCs) remains unclear. In this study, we investigated the effect of long-term mechanical stimulation on the attachment, osteogenic differentiation and mechanical properties of hASCs. Tailor-made, pneumatic cell stretching devices were used to expose hASCs to cyclic equiaxial stretching in osteogenic medium. Cell attachment and focal adhesions were visualised using immunocytochemical vinculin staining on days 3 and 6, and the proliferation and alkaline phosphatase activity, as a sign of early osteogenic differentiation, were analysed on days 0, 6 and 10. Furthermore, the mechanical properties of hASCs, in terms of apparent Young’s modulus and normalised contractility, were obtained using a combination of atomic force microscopy based indentation and computational approaches. Our results indicated that cyclic equiaxial stretching delayed proliferation and promoted osteogenic differentiation of hASCs. Stretching also reduced cell size and intensified focal adhesions and actin cytoskeleton. Moreover, cell stiffening was observed during osteogenic differentiation and especially under mechanical stimulation. These results suggest that cyclic equiaxial stretching modifies cell morphology, focal adhesion formation and mechanical properties of hASCs. This could be exploited to enhance osteogenic differentiation.
Graphical abstract
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Study of mesenchymal stem cells cultured on a poly(lactic-co-glycolic acid) scaffold containing simvastatin for bone healing | JABFM

Study of mesenchymal stem cells cultured on a poly(lactic-co-glycolic acid) scaffold containing simvastatin for bone healing | JABFM | Osteoporosis New drugs Review | Scoop.it
#openaccess Mesenchymal stem cells cultured on a #PLGA scaffold containing #simvastatin for #bonehealing https://t.co/bwdn7i37V3 #JABFM https://t.co/UURRN97HHR
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Synthesis of novel 5,6-dehydrokawain analogs as osteogenic inducers and their action mechanisms

Synthesis of novel 5,6-dehydrokawain analogs as osteogenic inducers and their action mechanisms | Osteoporosis New drugs Review | Scoop.it
Abstract An imbalance between bone resorption by osteoclasts and bone formation by osteoblasts can cause bone loss and bone-related disease. In a previous search for natural products that increase osteogenic activity, we found that 5,6-dehydrokawain (1) from Alpinia zerumbet promotes osteoblastogenesis. In this study, we synthesized and evaluated series of 5,6-dehydrokawain analogs. Our structure-activity relationships revealed that alkylation of para or meta position of aromatic ring of 1 promote osteogenic activity. Among the potential analogs we synthesized, (E)-6-(4-Ethylstyryl)-4-methoxy-2H-pyran-2-one (14) and (E)-6-(4-Butylstyryl)-4-methoxy-2H-pyran-2-one (21) both significantly up-regulated Runx2 and Osterix mRNA expression at 10 µM. These osteogenic activities could be mediated by bone morphogenetic protein (BMP) and activation of p38 MAPK signaling pathways. Compounds 14 and 21 also inhibited RANKL-induced osteoclast differentiation of RAW264 cells. These results indicated that novel 5,6-dehydrokawain analogs not only increase osteogenic activity but also inhibit osteoclast differentiation, and could be potential lead compounds for the development of anti-osteoporosis agents.
Krishan Maggon 's insight:
Bioorganic & Medicinal Chemistry Letters Available online 6 April 2017 In Press, Corrected Proof
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Stem cells survive 3D printing to produce growing cartilage

Stem cells survive 3D printing to produce growing cartilage | Osteoporosis New drugs Review | Scoop.it
Swedish printing technique opens the way to patients' own cells to repair cartilage.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Association between radiographic hand osteoarthritis and RANKL, OPG and inflammatory markers

Association between radiographic hand osteoarthritis and RANKL, OPG and inflammatory markers | Osteoporosis New drugs Review | Scoop.it
Conclusions This study strengthens the premise that OPG might be a valid biomarker of hand OA. Confirmation of these results in larger cohorts of patients will reinforce our theory that the RANKL/OPG pathway is a suitable target for developing novel agents against OA. 

Keywords Osteoarthritis; Hands; Inflammation markers
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Effects of Teriparatide on Joint Erosions in Rheumatoid Arthritis: A Randomized Controlled Trial

Effects of Teriparatide on Joint Erosions in Rheumatoid Arthritis: A Randomized Controlled Trial | Osteoporosis New drugs Review | Scoop.it
Background: Articular erosions correlate with disability in rheumatoid arthritis (RA). Biologic treatments for RA reduce erosion progression, but erosion healing occurs infrequently. The goal of thi
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Amgen, UCB Osteoporosis mAb Shows Phase III Efficacy but Has Serious Cardiac Risks | GEN Genetic Engineering & Biotechnology News - Biotech from Bench to Business | GEN

Amgen, UCB Osteoporosis mAb Shows Phase III Efficacy but Has Serious Cardiac Risks | GEN Genetic Engineering & Biotechnology News - Biotech from Bench to Business | GEN | Osteoporosis New drugs Review | Scoop.it
ARCH study evaluating sclerotin-targeting Evenity™ (romosozumab) met primary fracture reduction endpoints but therapy was associated with increased serious cardiovascular adverse events; firms say U.S. approval unlikely this year as FDA will evaluate ARCH data in addition to data from prior FRAME study
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

FDA Approves Radius Health's TYMLOS™ (abaloparatide), a Bone Building Agent for Postmenopausal Women with Osteoporosis 

FDA Approves Radius Health's TYMLOS™ (abaloparatide), a Bone Building Agent for Postmenopausal Women with Osteoporosis  | Osteoporosis New drugs Review | Scoop.it


TYMLOS is the first new anabolic (bone building) agent for postmenopausal women with osteoporosis in the United States in nearly 15 years US Commercial Launch in May Approval Based on Results at 18 months from the Landmark ACTIVE Trial and the first six months of ACTIVExtend Trial Nearly One in Two Women in the US Will Experience a


Clinical Data 


 The FDA's approval of TYMLOS was based on results at 18 months from the landmark ACTIVE trial and first six months of ACTIVExtend trial that demonstrated consistent significant and rapid reductions in the risk of vertebral and nonvertebral fractures regardless of age, years since menopause, presence or absence of prior fracture (vertebral or nonvertebral) and bone mineral density (BMD) at baseline. In human clinical studies, TYMLOS has been shown to decrease the incidence of new vertebral and nonvertebral fractures, to increase bone mineral density (BMD), and to increase a marker of bone formation. In addition, the anabolic effect of TYMLOS was demonstrated in animal studies by increases in BMD and bone mineral content that correlated with increases in bone strength at vertebral and/or nonvertebral sites. 


 The results from the ACTIVE trial were published in the Journal of the American Medical Association in August of 2016, and the results of the first six months of ACTIVExtend were published in the Mayo Clinic Proceedings in February 2017. Specifically, in the ACTIVE trial, TYMLOS demonstrated significant reductions in the relative risk of new vertebral and nonvertebral fractures compared to placebo in the ACTIVE trial of: 86% in new vertebral fractures 43% in nonvertebral fractures The absolute risk reductions were 3.6% and 2.0%, respectively.

Krishan Maggon 's insight:
About TYMLOS (abaloparatide) 

 TYMLOS (abaloparatide) was approved by the U.S. Food and Drug Administration or the treatment of postmenopausal women with osteoporosis at high risk for fracture defined as history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. Radius' Marketing Authorisation Application (MAA) for abaloparatide-SC for the treatment of women with postmenopausal osteoporosis was validated and is currently undergoing regulatory review by the European Medicines Agency (EMA). 

 Radius also is developing abaloparatide-transdermal (abaloparatide-TD) based on 3M's patented Microstructured Transdermal System technology for potential use as a treatment for postmenopausal women with osteoporosis.
more...
Krishan Maggon 's curator insight, May 19, 12:19 PM
TYMLOS (abaloparatide) was approved by the U.S. Food and Drug Administration or the treatment of postmenopausal women with osteoporosis at high risk for fracture defined as history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. 

Radius' Marketing Authorisation Application (MAA) for abaloparatide-SC for the treatment of women with postmenopausal osteoporosis was validated and is currently undergoing regulatory review by the European Medicines Agency (EMA). 

 Radius also is developing abaloparatide-transdermal (abaloparatide-TD) based on 3M's patented Microstructured Transdermal System technology for potential use as a treatment for postmenopausal women with osteoporosis.
Scooped by Krishan Maggon
Scoop.it!

Injured Bones Reconstructed by Gene and Stem Cell Therapies

Injured Bones Reconstructed by Gene and Stem Cell Therapies | Osteoporosis New drugs Review | Scoop.it
A Cedars-Sinai-led team of investigators has successfully repaired severe limb fractures in laboratory animals with an innovative technique that cues bone to regrow its own tissue. If found to be safe and effective in humans, the pioneering method of combining ultrasound, stem cell and gene therapies could eventually replace grafting as a way to mend severely broken bones.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Common Variants in OPG Confer Risk to Bone Mineral Density Variation and Osteoporosis Fractures

Common Variants in OPG Confer Risk to Bone Mineral Density Variation and Osteoporosis Fractures | Osteoporosis New drugs Review | Scoop.it
Abstract Although many common variants have been identified for bone mineral density (BMD) and osteoporosis fractures, all the identified risk variants could only explain a small portion of heritability of BMD and osteoporosis fractures. OPG belongs to the tumor necrosis factor receptor superfamily, which plays a crucial role in bone remodeling and is thus a promising candidate gene of osteoporosis. Several studies have explored the association of OPG variants with BMD or osteoporosis fractures, however, the results remain inconsistent among different populations. In the study, we first assessed the relationship between OPG variants and BMD or osteoporosis fractures in our sample size (227 subjects with postmenopausal osteoporosis and 189 controls), and then performed a systematic meta-analysis. Among the nine SNPs genotyped, rs6469804 and rs2073618 showed significant associations with both BMD and osteoporotic fractures, while rs3102735 was only associated with BMD in our samples (P < 0.05). For meta-analyses, data for a total of 12 SNPs were pooled (4725 patients and 37804 controls), and five SNPs, including rs6993813, rs6469804, rs3134070, rs2073618 and rs3102734, showed association with osteoporosis fractures (P < 0.05). On light of the above analysis, we believe that OPG is one promising susceptibility gene of BMD or osteoporotic fractures.
Krishan Maggon 's insight:
Xiaoyong Sheng, Guangyong Cai, Xingjun Gong, Zouying Yao & Ye Zhu

Scientific Reports 7, Article number: 1739 (2017)

doi:10.1038/s41598-017-01579-6
Published online: 11 May 2017
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Increasing Human Neural Stem Cell Transplantation Dose Alters Oligodendroglial and Neuronal Differentiation after Spinal Cord Injury

Increasing Human Neural Stem Cell Transplantation Dose Alters Oligodendroglial and Neuronal Differentiation after Spinal Cord Injury | Osteoporosis New drugs Review | Scoop.it
In this article, Piltti and colleagues investigate the effect of human neural stem
cell transplant dose on engraftment, death, differentiation, lineage-specific migration,
and recovery of sensory and locomotor function after spinal cord injury. The data
indicate that the effect of dose should be considered in the development of clinical
cell transplantation protocols.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

CRISPR-SMART Cells Regenerate Cartilage, Secrete Anti-Arthritis Drug | GEN Genetic Engineering & Biotechnology News - Biotech from Bench to Business | GEN

CRISPR-SMART Cells Regenerate Cartilage, Secrete Anti-Arthritis Drug | GEN Genetic Engineering & Biotechnology News - Biotech from Bench to Business | GEN | Osteoporosis New drugs Review | Scoop.it
Get the latest in biotechnology through daily news coverage as well as analysis, features, tutorials, webinars, podcasts, and blogs. Learn about the entire bioproduct life cycle from early-stage R&D, to applied research including omics, biomarkers, as well as diagnostics, to bioprocessing and commercialization.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Clinical efficacy and safety of mesenchymal stem cell transplantation for osteoarthritis treatment: A meta-analysis

Clinical efficacy and safety of mesenchymal stem cell transplantation for osteoarthritis treatment: A meta-analysis | Osteoporosis New drugs Review | Scoop.it
Purpose The aim of this study was to evaluate the therapeutic efficacy and safety of mesenchymal stem cells (MSCs) for the treatment of patients with knee osteoarthritis (OA). Materials We performed a meta-analysis of relevant published clinical studies. An electronic search was conducted for randomized controlled trials (RCTs) of MSC-based therapy in knee OA. The visual analogue scale (VAS), International Knee Documentation Committee (IKDC) form, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Lequesne algofunctional indices (Lequesne), Lysholm knee scale (Lysholm), Tegner activity scale (Tegner) and adverse events (AEs) were evaluated. Results Eleven eligible trials with 582 knee OA patients were included in the present meta-analysis. We demonstrated that MSC treatment could significantly decrease VAS and increase IKDC scoresafter a 24-month follow-up compared with controls (P<0.05). MSC therapy also showed significant decreases in WOMAC and Lequesne scores after the 12-month follow-up (P<0.01). Analysis of Lysholm (24-month) and Tegner (12- and 24-month) scores also demonstrated favorable results for MSC treatment (P<0.05). Conclusion Overall, MSC transplantation treatment was shown to be safe and has great potential as an efficacious clinical therapy for patients with knee OA.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Human Kunitz-type protease inhibitor engineered for enhanced matrix retention extends longevity of fibrin biomaterials

Human Kunitz-type protease inhibitor engineered for enhanced matrix retention extends longevity of fibrin biomaterials | Osteoporosis New drugs Review | Scoop.it
Publication date: August 2017
Source:Biomaterials, Volume 135
Author(s): Priscilla S. Briquez, Kristen M. Lorentz, Hans M. Larsson, Peter Frey, Jeffrey A. Hubbell
Aprotinin is a broad-spectrum serine protease inhibitor used in the clinic as an anti-fibrinolytic agent in fibrin-based tissue sealants. However, upon re-exposure, some patients suffer from hypersensitivity immune reactions likely related to the bovine origin of aprotinin. Here, we aimed to develop a human-derived substitute to aprotinin. Based on sequence homology analyses, we identified the Kunitz-type protease inhibitor (KPI) domain of human amyloid-β A4 precursor protein as being a potential candidate. While KPI has a lower intrinsic anti-fibrinolytic activity than aprotinin, we reasoned that its efficacy is additionally limited by its fast release from fibrin material, just as aprotinin's is. Thus, we engineered KPI variants for controlled retention in fibrin biomaterials, using either covalent binding through incorporation of a substrate for the coagulation transglutaminase Factor XIIIa or through engineering of extracellular matrix protein super-affinity domains for sequestration into fibrin. We showed that both engineered KPI variants significantly slowed plasmin-mediated fibrinolysis in vitro, outperforming aprotinin. In vivo, our best engineered KPI variant (incorporating the transglutaminase substrate) extended fibrin matrix longevity by 50%, at a dose at which aprotinin did not show efficacy, thus qualifying it as a competitive substitute of aprotinin in fibrin sealants.
Graphical abstract
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Researchers 3D Print Cartilage with Stem Cells Taken from Human Knee

Researchers 3D Print Cartilage with Stem Cells Taken from Human Knee | Osteoporosis New drugs Review | Scoop.it
One of the challenges of 3D bioprinting is getting the stem cells which make up the biological ink to survive the 3D printing process - not to mention keeping them viable long enough to grow into a full tissue structure.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Aesculin modulates bone metabolism by suppressing receptor activator of NF-κB ligand (RANKL)-induced osteoclastogenesis and transduction signals

Aesculin modulates bone metabolism by suppressing receptor activator of NF-κB ligand (RANKL)-induced osteoclastogenesis and transduction signals | Osteoporosis New drugs Review | Scoop.it
Highlights 
Aesculin (AES), a coumarin compound derived from Aesculus hippocasanum L, is reported to exert protective role against inflammatory diseases, gastric disease and cancer. However, direct effect of AES in bone metabolism is deficient.
• AES inhibits RANKL-induced osteoclast formation and function within non-toxic concentrations. 
• AES suppresses RANKL-induced MAPKs and NF-κB signaling pathways. 
• RANK expression is affected by AES during osteoclastogenesis. • AES prevents bone mass loss in osteoporosis animal model.


Krishan Maggon 's insight:
Biochemical and Biophysical Research Communications Available online 29 April 2017 In Press, Accepted Manuscript
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Identification of Three Early Phases of Cell-Fate Determination during Osteogenic and Adipogenic Differentiation by Transcription Factor Dynamics

Identification of Three Early Phases of Cell-Fate Determination during Osteogenic and Adipogenic Differentiation by Transcription Factor Dynamics | Osteoporosis New drugs Review | Scoop.it
In this article, van Leeuwen and colleagues determine high temporal gene expression
changes in human mesenchymal stromal cells upon induction of adipocyte and osteoblast
differentiation. They identify three early differentiation phases within the first
4 days. Furthermore, novel transcription factors were identified that may control
cell fate of hMSCs and should be considered in mechanistic models that clarify bone-anabolic
changes.
more...
No comment yet.